Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New stem cell approach aims to tame rare genetic diseases

NCT ID NCT02171104

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a stem cell transplant method for people with inherited metabolic disorders and severe osteopetrosis. The goal is to get the donor cells to take hold while keeping side effects low. Participants receive chemotherapy drugs before the transplant to prepare their bodies. The trial includes 149 people aged 0 to 55.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
stem cell transplant with chemotherapy drugs (busulfan, fludarabine, and sometimes ATG or other agents)
What this could lead to
If successful, this could offer a way to slow or stop the progression of severe inherited metabolic disorders and osteopetrosis, potentially improving quality of life and survival.
What could go wrong
This is a phase 2 trial with 149 participants, so results are still early. The transplant procedure carries serious risks, including graft failure, severe infections, and organ damage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

149 people

The number who actually took part.

Started

Jul 2014

Expected to finish

Jul 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

Up to 55 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * 0 through 55 years of age * Adequate graft available * Adequate organ function * Eligible Diseases: * Mucopolysaccharidosis Disorders: * MPS IH (Hurler syndrome) * MPS II (Hunter syndrome) if the patient has no or minimal evidence of symptomatic neurologic disease but is expected to have a neurologic phenotype * MPS VI (Maroteaux-Lamy syndrome) * MPS VII (Sly syndrome) * Glycoprotein Metabolic Disorders: * Alpha mannosidosis * Fucosidosis * Aspartylglucosaminuria * Sphingolipidoses and Recessive Leukodystrophies: * Globoid cell leukodystrophy * Metachromatic leukodystrophy * Niemann-Pick B patients (sphingomyelin deficiency) * Niemann-Pick C subtype 2 * Peroxisomal Disorders: * Adrenoleukodystrophy with cerebral involvement * Zellweger syndrome * Neonatal Adrenoleukodystrophy * Infantile Refsum disease * Acyl-CoA-Oxidase Deficiency * D-Bifunctional enzyme deficiency * Multifunctional enzyme deficiency * Alpha-methylacyl-CoA Racmase Deficiency (AMACRD) * Mitochondrial Neurogastrointestingal Encephalopathy (MNGIE) * Severe Osteopetrosis (OP) * Hereditary Leukoencephalopathy with axonal spheroids (HDLS; CSF1R mutation) * Other Inherited Metabolic Disorders (IMD): Patients will also be considered who have other life-threatening, rare lysosomal, peroxisomal or other similar inherited disorders characterized by white matter disease or other neurologic manifestations for which there is rationale that transplantation would be of benefit, such as certain patients with Wolman's disease, GM1 gangliosidosis, I-cell disease, Tay-Sachs disease, Sandhoff disease or others. * Voluntary written consent Exclusion Criteria: * Pregnancy - menstruating females must have a negative serum or urine pregnancy test within 14 days of study treatment start * Prior myeloablative chemotherapy exposure within 4 months of the start of conditioning on this protocol (patients excluded for this reason may be eligible for other institutional protocols) * Uncontrolled bacterial, fungal or viral infections including HIV (including active infection with Aspergillus or other mold within 30 days)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acyl-coa oxidase deficiency are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Masonic Cancer Center, University of Minnesota

    Minneapolis, Minnesota, 55455, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.